Evropská unie - maltština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psorajiżi - immunosoppressanti - treatment of moderate-to-severe plaque psoriasis in adults.

Evropská unie - maltština - EMA (European Medicines Agency)

eco animal health europe limited - tylvalosin - antiinfectives għall-użu sistemiku, sustanza antibatterika għal użu sistemiku, il-makrolidi - pheasants; chicken; turkeys; pigs - pigstreatment u methaphylaxis tal-pnewmonja enżootika tal-qżieqeż;it-trattament tal-ħnieżer proliferattiva tal-majjali (ileitis);it-trattament u l-methaphylaxis tad-disinterija tal-qżieqeż. chickenstreatment u methaphylaxis ta 'mard respiratorju marbut ma' mycoplasma gallisepticum fit-tiġieġ. pheasantstreatment ta 'mard respiratorju marbut ma' mycoplasma gallisepticum. turkeystreatment ta 'mard respiratorju marbut ma' tylvalosin strejns sensittivi ta ' ornithobacterium rhinotracheale fid-dundjani.

Evropská unie - maltština - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - strain mycoplasma synoviae ms-h - immunoloġiċi għall-aves, jgħixu vaċċini batterjali - chicken - għall-immunizzazzjoni attiva tal-futur tal-brojlers irabbi-tiġieġ, fil-futur saff irabbi-tiġieġ u l-futur saff-tiġieġ sabiex jitnaqqsu l-arja sac-leżjonijiet u jnaqqsu l-għadd tal-bajd bil-qoxra mhux normali formazzjoni kkawżati minn mycoplasma synoviae.

Evropská unie - maltština - EMA (European Medicines Agency)

ceva santé animale - cabergoline - prolactine tal-protease, genito sistema urinarja u l-ormoni tas-sess, oħra gynecologicals - għall-użu fil-merħla-programm tal-ġestjoni tal-baqar tal-ħalib bħala għajnuna fil-f'daqqa t-tnixxif-off mill-tnaqqis tal-produzzjoni tal-ħalib li:inaqqsu l-ħalib tnixxija mill-tnixxif off;jitnaqqas ir-riskju ta ' l-ġodda intramammarja l-infezzjonijiet matul il-perjodu xott;tnaqqas l-iskumdità.

Evropská unie - maltština - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine, zidovudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Evropská unie - maltština - EMA (European Medicines Agency)

teva pharma b.v.  - lamivudine, zidovudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - lamivudine / zidovudine teva huwa indikat fit-terapija kombinata antiretrovirali għat-trattament tal-infezzjoni tal-virus tal-immunodefiċjenza umana (hiv).

Evropská unie - maltština - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - neoplażmi pankreatiċi - aġenti antineoplastiċi - trattament ta ' adenocarcinoma metastatic ta-pancreas, flimkien ma ' 5 fluorouracil (artikolu 5) u leucovorin (lv), fil-pazjenti adulti li wettqu wara gemcitabine bbażati fuq terapija.

Evropská unie - maltština - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - aġenti antineoplastiċi - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Evropská unie - maltština - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Evropská unie - maltština - EMA (European Medicines Agency)

biomarin international limited - sapropterin dihydrochloride - phenylketonurias - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - kuvan huwa indikat għall-kura ta 'hyperphenylalaninemia (hpa) f'adulti u pazjenti pedjatriċi ta' kull età b'fenilketonurja (pku) li ntwera li jirrispondu għal trattament bħal dan. kuvan huwa indikat ukoll għal-kura ta 'hyperphenylalaninaemia (hpa) f'persuni adulti u pazjenti tfal ta' kull età b'defiċjenza ta ' tetrahydrobiopterin (bh4) u li jkunu wrew rispons għal din il-kura.